Drägerwerk Surges: Record Sales, 20% EBIT Gain, and 3‑Year Dividend Growth Drive Investor Appeal
Drägerwerk’s record 2025 sales, 20% EBIT rise, soaring order book and third straight dividend hike prove a resilient, shareholder‑friendly growth story that outpaces tough market conditions.
3 minutes to read



